This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Adess, M. Articles by Wehrmacher, W. H. Search for Related Content PubMed PubMed Citation Articles by Adess, M. Articles by Wehrmacher, W. H. Pubmed/NCBI databases Medline Plus Health Information Cancer Social Bookmarking                         What's this?

Thromboembolism in Cancer Patients: Pathogenesis and Treatment

Robert Eisner, DO

Sucha Nand, MD

John Godwin, MD

Harry L. Messmore, Jr, MD

William H. Wehrmacher, MD

Loyola University Stritch School of Medicine, Maywood, IL, USA, and Hines Veterans Affairs Hospital, Hines, IL, USA

In this review we summarize the causes of cancer related thrombosis as well as modern treatment approaches. Malignancy as a risk factor for thromboembolism is becoming increasingly recognized by clinicians caring for these patients. The probability of thrombosis occurring in an individual patient is dependent on several factors, including accompanying medical problems, the type of cancer, the clinical stage, performance status, and the treatment modalities employed. Thrombophilia with a history of thromboembolism is important as well. The overall risk of thrombosis is sevenfold that of noncancer patients. Though much has been learned about the pathogenesis of cancer-related thrombosis, we are in fact just beginning to understand the cross-talk between cancer cells and their related microenvironment, and such investigations are likely to increase our knowledge of cancer-related thrombosis mechanisms. Research in these areas may also suggest new strategies for cancer prevention, metastasis suppression, and new treatments. Drugs used in cancer therapy are increasingly recognized to directly contribute to the thrombotic tendency. Few studies provide data on the optimal management of cancer patients with thrombosis. It has been learned that retreating with the same drug can be very hazardous. In general the approach to prevention of thrombosis is the same as for noncancer patients, recognizing that specific cancer types and stage can place a patient in a high-risk category. Initial coumadin therapy fails in a significant number of patients with cancer. Recognition of the cancer patients at highest risk for coumadin failure is challenging. Low-molecular-weight heparins appear to be more effective in such situations where coumadin is likely to fail or has failed, but these drugs are thought to be costlier. Newer agents such as Factor Xa inhibitors and TF inhibitors are currently under investigation and may be found useful in the management of cancer-related thrombosis.

Key Words: Cancer • Thromboembolism • Anticoagulants • Chemotherapy • Cancer pro-coagulants

Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 3, 254-266 (2006)
DOI: 10.1177/1076029606291432


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Nguyen, S.-J. Lee, E. Libby, and C. Verschraegen Rate of Thromboembolic Events in Mesothelioma Ann. Thorac. Surg., March 1, 2008; 85(3): 1032 - 1038. [Abstract] [Full Text] [PDF]